Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
4
×
life sciences
national blog main
patisiran
4
×
alnylam pharmaceuticals
boston
fda
national top stories
onpattro
rna interference
akcea therapeutics
drugs
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
anylam pharmaceuticals
biotech
boehringer ingelheim
cardiomyopathy
craig mello
deals
dicerna pharamceuticals
givosiran
hepatitis b
hepatitis b virus
john maraganore
neuropathy
new york
What
drug
4
×
alnylam
fda
pharmaceuticals
ago
approved
disease
medicine
medicines
rnai
afternoon
akcea
alnylam’s
amyloidosis
approval
attr
available
battle
caught
causing
debilitating
dicerna
eye
gene
genetic
gets
hepatitis
history
indicated
intended
interference
landmark
making
nod
ok
oks
onpattro
patients
patisiran
pay
Language
unset
Current search:
patisiran
×
drug
×
" clinical trials "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug